Poly Medicure Limited has informed the Exchange about Revised Press/Media Release
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure has announced a revised press release (replacing its 24 September 2025 intimation) confirming the acquisition of 100% stake in Italy-based Medistream SA, which includes Citieffe SRL and its US and Mexico subsidiaries. The deal is valued at an Enterprise Value of INR 324 crore (EUR 31 million), translating to 10.2x EV/EBITDA on FY24 numbers. Citieffe is an orthopaedic trauma and extremities specialist with EUR 17.3 million revenue and EUR 3.1 million EBITDA in CY 2024 (15% and 14% YoY growth respectively), 45 patents, FDA and EU MDR clearances, and direct operations in Italy, USA, and Mexico with 25+ country distribution. This is Poly Medicure's second acquisition in roughly a month and marks its entry into the global orthopaedics segment. The transaction is expected to close within 4-8 weeks, subject to customary approvals, with Citieffe's existing CEO Pascal Govi continuing to lead the business.
The acquisition expands Poly Medicure into a higher-margin, faster-growing orthopaedics segment and adds a direct US sales footprint, which should support long-term revenue and margin growth. Near-term EPS may see some dilution given the INR 324 crore outlay, but cost synergies from manufacturing in India and cross-selling could drive meaningful value creation once integrated.